A small molecule targeting CHI3L1 inhibits lung metastasis by blocking IL‐13Rα2‐mediated JNK‐AP‐1 signals

Autor: Jae-Kyung Jung, Dong Hun Lee, Yong Sun Lee, Sang-Bae Han, Dong Ju Son, Jaesuk Yun, Hee Pom Lee, Ki Cheon Kim, Ji Eun Yu, Jin Tae Hong, Young Wan Ham, Nam Du Kim
Rok vydání: 2021
Předmět:
Zdroj: Molecular Oncology
Molecular Oncology, Vol 16, Iss 2, Pp 508-526 (2022)
ISSN: 1878-0261
1574-7891
DOI: 10.1002/1878-0261.13138
Popis: Our previous big data analyses showed a high level of association between chitinase 3 like1 (CHI3L1) expression and lung tumor development. In the present study, we investigated whether a CHI3L1‐inhibiting chemical, 2‐({3‐[2‐(1‐cyclohexen‐1‐yl)ethyl]‐6,7‐dimethoxy‐4‐oxo‐3,4‐dihydro‐2‐quinazolinyl}sulfanyl)‐N‐(4‐ethylphenyl)butanamide (K284), could inhibit lung metastasis and studied its mechanism of action. We investigated the antitumor effect of K284 both in vitro and in vivo. K284 (0.5 mg·kg−1 body weight) significantly inhibited lung metastasis in in vivo models after injection of murine melanoma cells (B16F10) or adenocarcinomic human alveolar basal epithelial cells (A549). K284 significantly and concentration‐dependently also inhibited cancer cell proliferation and migration in the A549 and H460 lung cancer cell lines. We found that the binding of K284 to the chitin‐binding domain (CBD) of CHI3L1 prevented the binding of CHI3L1 to its receptor, interleukin‐13 receptor subunit alpha‐2 (IL‐13Rα2), thereby suppressing the CHI3L1 signal. This blocking of the CHI3L1‐IL‐13Rα2 signal caused the inhibition of c‐Jun N‐terminal kinase (JNK)‐activator protein 1 (AP‐1) signals, resulting in the prevention of lung metastasis and cancer cell growth. Our data demonstrate that K284 may serve as a potential candidate anticancer compound targeting CHI3L1.
High serum levels of CHI3L1 correlate with poor prognosis and survival in various human carcinomas, including lung cancer. We demonstrated that the selective CHI3L1 inhibitor K284 strongly inhibits lung cancer cell growth and tumor metastasis. K284 inhibited CHI3L1‐IL‐13Rα2 signaling and its downstream pathways. This study indicates K284 as a potential anticancer drug candidate that targets CHI3L1 to block IL‐13Rα2‐mediated JNK‐AP‐1 signaling.
Databáze: OpenAIRE
Externí odkaz: